Table 2.

Summary of clinical studies that evaluated hematopoietic stem cell transplantation in T-PLL

Study design	n	Age [years]	Relapse rate [%]	TRM [%]	Pre-HSCT CR [%]	Post-HSCT CR [%]	PFS [mo]	OS	Reference
Summary of clinical studies on auto-HSCT in T-PLL
Multi-center, retrospective	15	58	60	7	87	100	n.a.	52 mo	[42]
Summary of clinical studies on allo-HSCT in T-PLL
Multicenter, retrospective	13	51	33	31	69	92	n.a.	33mo	[42]
CIBMTR registry, retrospective	21	54	39*	28*	n.a.	n.a.	5.1	11.2mo	[43]
EBMT registry, retrospective	41	51	41**	41**	27	n.a.	10	21%**	[41]
Multicenter, prospective	5	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	24.8mo	[5]
French Society of SCT, retrospective	27	53	47	31**	52	78	26**	36%**	[44]
Single-center, retrospective	11	56	21***	34***	91	91	15	56mo	[45]
EBMT registry, prospective (a)	37	56	38***	32***	62	n.a.	30***	42%***	[47••]
TRUMP registry, retrospective	20	54	69.6**	20.9*	30	n.a.	33.5%**	40%**	[46]

(a) Patients < 65 years, with progressive disease, with a mismatched unrelated donor or with cord blood were excluded

*at one year

**at three years

***at four years

EBMT: European Society for Blood and Marrow Transplantation; CIBMTR: Center for International Blood and Marrow Transplant Research; TRUMP: Transplant Registry Unified Management Program, Japan